List of Excipients in Branded Drug THYROGEN

« Back to Dashboard

Thyrogen Excipient Strategy and Commercial Opportunities in Recombinant TSH

Last updated: August 10, 2026

Thyrogen, or thyrotropin alfa, is a lyophilized recombinant human thyroid-stimulating hormone product used in differentiated thyroid cancer management. Its current formulation uses mannitol, sodium chloride, and phosphate buffers to support cake structure, isotonicity, and pH control. The strongest commercial opportunities are in supply-chain resilience, improved lyophilized presentations, low-volume biologic manufacturing, and follow-on recombinant TSH products rather than in conventional generic substitution.

What is Thyrogen and how is it formulated?

Thyrogen is a recombinant human thyroid-stimulating hormone administered by intramuscular injection. Genzyme, now part of Sanofi, developed the product. The U.S. Food and Drug Administration approved Thyrogen in 1998 under Biologics License Application No. 103964. The product is used to stimulate radioiodine uptake and thyroglobulin production without requiring patients to stop thyroid hormone replacement therapy.[1]

The marketed product is supplied as a sterile, preservative-free, single-dose lyophilized powder.

Product attribute	Thyrogen profile
Active ingredient	Thyrotropin alfa
Biological class	Recombinant human glycoprotein hormone
Dose strength	0.9 mg per vial
Route	Intramuscular injection
Dosage form	Lyophilized powder for reconstitution
Reconstitution volume	1.2 mL sterile water for injection, with 1 mL administered
Main indications	Radioiodine remnant ablation, diagnostic radioiodine imaging, stimulated serum thyroglobulin testing
Manufacturer	Sanofi
U.S. approval	1998
Preservative	None

The vial contains more protein than the labeled delivered dose to account for product handling and reconstitution. After reconstitution, the solution is intended for immediate use and is not formulated as a multidose product.[1]

What excipients are used in Thyrogen?

The U.S. prescribing information identifies four principal excipient categories:

Excipient	Primary formulation function	Commercial relevance
Mannitol	Bulking agent and lyophilization matrix component	Supports cake formation and contributes to product elegance
Sodium chloride	Tonicity modifier	Helps produce an injection compatible with intramuscular administration
Sodium phosphate dibasic	Buffer component	Controls pH during manufacture and storage
Sodium phosphate monobasic	Buffer component	Completes the phosphate buffer system

The formulation does not rely on preservatives, surfactants, or complex lipid excipients. This relatively simple composition reduces excipient-related regulatory burden but places greater importance on protein stability, freeze-drying conditions, container closure integrity, and reconstitution performance.

Why is mannitol used in Thyrogen?

Mannitol has two practical roles in a lyophilized biologic. It provides solid mass for a physically acceptable lyophilized cake and can improve the visual and handling properties of the finished vial. In protein formulations, mannitol is often evaluated as a bulking agent rather than as the sole stabilizer because it may crystallize during freezing or drying. That behavior can affect protein distribution and cake morphology.

For Thyrogen, mannitol is part of a formulation system that also includes phosphate salts and sodium chloride. A change in mannitol grade, particle characteristics, endotoxin profile, or crystallization behavior could alter the freeze-drying cycle and reconstitution profile.

What is the role of phosphate buffers?

The monobasic and dibasic sodium phosphate pair establishes the formulation pH. Recombinant glycoproteins can be sensitive to pH shifts, aggregation, deamidation, oxidation, and charge-variant formation. Phosphate selection therefore affects both product stability and the comparability package required for a formulation change.

Phosphate buffers are commercially familiar and inexpensive. Their strategic value is not price. It is consistency of pharmaceutical grade, low bioburden, low endotoxin, and control of trace metals and particulate matter.

Does Thyrogen contain sucrose, trehalose, or polysorbate?

The U.S. label does not identify sucrose, trehalose, polysorbate 20, or polysorbate 80 as Thyrogen excipients.[1] This creates a clear formulation-development boundary. A reformulated product that introduces a sugar stabilizer or surfactant would require evidence that the new excipient improves stability without changing immunogenicity, aggregation, potency, injection performance, or clinical behavior.

What excipient strategy does Thyrogen use?

Thyrogen uses a low-complexity lyophilized formulation built around four objectives:

1. Preserve thyrotropin alfa activity during freezing, primary drying, secondary drying, and storage.
2. Produce a robust cake that can be reconstituted rapidly and consistently.
3. Maintain a suitable pH and osmolality for intramuscular injection.
4. Avoid preservatives and unnecessary formulation components in a single-dose biologic.

The formulation strategy is conservative. It relies on widely accepted pharmaceutical excipients and a validated lyophilization process instead of a proprietary delivery platform.

That approach has commercial advantages. It simplifies procurement, facilitates global regulatory filings, and reduces the number of formulation variables in a comparability assessment. It also limits differentiation. A competitor cannot easily create a premium product merely by replacing one conventional buffer or bulking agent.

What commercial opportunities exist for Thyrogen excipient suppliers?

The direct excipient value per vial is modest. The larger opportunity is participation in a qualified biologic supply chain where formulation changes can trigger extensive process validation and regulatory review.

High-value opportunities

Pharmaceutical-grade mannitol supply

Mannitol suppliers can compete on:

• Lot-to-lot crystallinity and polymorph control
• Low endotoxin and bioburden
• Particle-size consistency
• Reliable global supply
• Documentation supporting biologic manufacturing
• Qualification of alternate manufacturing sites

A supplier that can demonstrate consistent behavior in the specific Thyrogen lyophilization cycle has greater value than a commodity supplier offering only a lower unit price.

Phosphate buffer supply

Phosphate salts are low-cost materials, but biologic manufacturers require tight control of impurities, microbial quality, and trace metals. Opportunities exist for dual sourcing, regional supply, and validated substitution between qualified grades.

Sodium chloride for injectable manufacturing

Sodium chloride is a commodity excipient, but injectable-grade supply is subject to stricter quality requirements than general industrial material. The opportunity is mainly supply continuity, packaging, and regional qualification rather than formulation differentiation.

Lyophilization development services

Contract development and manufacturing organizations can offer value through:

• Cycle optimization
• Shelf-temperature and chamber-pressure control
• Cake appearance improvement
• Reduced residual moisture
• Faster reconstitution
• Container closure integrity testing
• Scale-up from development to commercial lyophilizers

For a recombinant protein product, the lyophilization cycle can be as commercially important as the excipient composition.

What reformulation opportunities exist for Thyrogen?

Potential reformulation programs fall into four categories.

Reformulation concept	Potential benefit	Principal development risk
Mannitol plus sucrose or trehalose	Improved protein stabilization	New degradation profile and comparability burden
Surfactant-containing formulation	Reduced interface-induced aggregation	Oxidation, peroxide impurities, and injection compatibility
More concentrated liquid formulation	Lower preparation burden	Reduced shelf life and higher aggregation risk
Ready-to-use or dual-chamber presentation	Reduced reconstitution error	Device validation, cost, and container compatibility

Liquid Thyrogen formulation

A ready-to-use liquid could improve pharmacy workflow and reduce reconstitution steps. The technical barrier is substantial. Liquid storage exposes thyrotropin alfa to longer periods of hydrolysis, oxidation, aggregation, and surface adsorption. A liquid product may require a different stabilizer system, surfactant, container, and cold-chain profile.

The commercial case would depend on whether hospitals value reduced preparation time enough to support a higher price. Because Thyrogen is generally administered in specialty settings, preparation simplification could support adoption, but the product would compete against an established vial and reconstitution process.

Dual-chamber syringe or vial

A dual-chamber system could separate the lyophilized protein from the diluent until administration. This could reduce operator handling and improve dose preparation consistency. It would also increase device cost and introduce new extractables, leachables, sterility, and human-factors requirements.

Alternative stabilizers

Trehalose and sucrose are conventional protein stabilizers. Either could support a new formulation, but the inclusion of a sugar would not by itself create durable commercial differentiation. The value would come from a demonstrated improvement in shelf life, reduced aggregation, improved temperature tolerance, or a less demanding distribution model.

What patents protect Thyrogen and its excipient formulation?

Thyrogen is a biologic product rather than a conventional small-molecule drug. Its protection can include composition-of-matter claims for recombinant thyrotropin alfa, host-cell and production claims, purification claims, formulation claims, manufacturing processes, and method-of-use claims.

The original commercial product dates to 1998. Any original patent estate would have been subject to the standard U.S. patent term rules applicable to its filing dates, including possible patent-term adjustment or extension. The original regulatory exclusivity period for a biologic approved before the modern biosimilar framework would not be the principal current barrier to a follow-on product.

No current Orange Book patent listing should be assumed for Thyrogen. Biologics are generally managed through the Purple Book and BLA framework rather than Orange Book approval pathways. A follow-on thyrotropin alfa would be evaluated under section 351(k) of the Public Health Service Act or as a standalone biologic under section 351(a), depending on the sponsor's development strategy.[2]

A formulation patent would need to claim more than the use of common excipients in routine amounts. Stronger claims would likely require a defined excipient ratio, specific stability result, lyophilization profile, reconstitution property, or measurable product-quality advantage.

When does Thyrogen lose exclusivity?

Thyrogen's practical market protection has already moved beyond the original launch exclusivity period. The relevant barriers are now:

• Product-specific manufacturing know-how
• Analytical similarity and potency testing
• Clinical or pharmacodynamic bridging requirements
• Regulatory development cost
• Physician and nuclear-medicine center familiarity
• Sanofi's established supply chain
• Patent claims that remain enforceable, if any
• Market size relative to the cost of developing a follow-on biologic

The absence of a conventional generic pathway is important. A company cannot launch an ordinary ANDA generic version of thyrotropin alfa because Thyrogen is a biologic. A follow-on developer would need to establish analytical and functional comparability and address residual clinical or immunogenicity questions under the applicable FDA pathway.[2]

Are there biosimilar or generic competitors to Thyrogen?

Thyrogen has no conventional small-molecule generic equivalent. A biosimilar or follow-on recombinant human TSH product would need to match the reference product across multiple dimensions:

• Primary amino acid sequence
• Glycosylation profile
• Higher-order structure
• Receptor-binding activity
• Cell-based potency
• Aggregation and degradation profile
• Host-cell protein and DNA controls
• Immunogenicity risk
• Pharmacokinetic and pharmacodynamic behavior

Thyrotropin alfa is a glycoprotein, so glycosylation control is a central barrier. A competitor with a different host cell, purification process, or formulation may produce a clinically active molecule but still face a significant comparability program.

What Paragraph IV challenges affect Thyrogen?

Paragraph IV litigation is associated with abbreviated new drug applications for small-molecule products listed in the Orange Book. Because Thyrogen is a biologic, a Paragraph IV challenge is not the expected pathway for a follow-on product.

The relevant competitive mechanism is a 351(k) biosimilar application, a 351(a) standalone BLA, or a potential patent dispute involving process, formulation, or method-of-use claims. Any litigation risk would likely focus on patent validity, infringement, regulatory exclusivity, or the scope of the reference-product patent estate rather than an Orange Book certification.

What FDA regulatory status does Thyrogen have?

Thyrogen is FDA-approved under a BLA and is regulated as a biologic. The product is not a vaccine, antibody, or cell therapy. It is a recombinant protein hormone used in thyroid cancer diagnostics and preparation for radioiodine therapy.

The dosing regimen typically involves two 0.9 mg intramuscular injections given 24 hours apart. For radioiodine imaging or ablation, radioactive iodine is generally administered after the second injection, followed by imaging or treatment according to the approved protocol.[1]

The principal regulatory issues for an excipient or presentation change are likely to include:

• Product quality comparability
• Protein aggregation
• Potency retention
• Glycosylation and charge variants
• Sterility assurance
• Reconstitution time
• Container closure integrity
• Stability under labeled storage conditions
• Extractables and leachables for a new delivery device

How strong is the Thyrogen patent estate?

The commercial strength of Thyrogen's estate is likely lower than its manufacturing and regulatory barriers. The product uses conventional excipients, and broad claims covering mannitol, phosphate, and sodium chloride would be difficult to distinguish from established formulation practice without narrow structural or performance limitations.

The strongest defensible positions would generally be:

• Defined recombinant thyrotropin alfa production methods
• Specific purification or glycosylation-control methods
• Narrow stability-enhancing formulations
• Proprietary lyophilization parameters linked to product quality
• Combination or method-of-use claims tied to a defined thyroid cancer protocol

The most credible competitive moat is therefore a combined package of biologic analytics, process control, clinical familiarity, and supply reliability.

What generic launch risks exist for a Thyrogen competitor?

A follow-on developer would face several launch scenarios.

Launch scenario	Commercial effect
First 351(k) approval with no litigation delay	Potential rapid price competition in specialty centers
351(a) product with limited interchangeability positioning	Slower substitution and higher medical-affairs burden
Improved liquid or device presentation	Premium positioning if workflow benefits are demonstrated
Regional or hospital-contract launch	Targeted share capture without broad physician switching
Patent or regulatory dispute	Delayed entry and higher legal cost
Manufacturing failure or supply interruption	Significant vulnerability because the product is a specialized biologic

A low-price strategy alone may not be sufficient. The addressable market is specialized, and hospitals may prioritize uninterrupted supply, validated preparation, and predictable reimbursement over modest vial discounts.

How does Thyrogen compare with alternative thyroid cancer preparation strategies?

The main alternative to recombinant TSH stimulation is withdrawal of thyroid hormone therapy to allow endogenous TSH elevation. Withdrawal avoids the acquisition cost of Thyrogen but can cause hypothyroid symptoms and disrupt work, driving, and routine care.

Factor	Thyrogen	Thyroid hormone withdrawal
TSH elevation	Pharmacologic	Endogenous
Patient hypothyroidism	Generally avoided	Expected during withdrawal
Product cost	High pharmaceutical cost	Lower direct drug cost
Workflow	Two injections and scheduled testing	Hormone interruption and recovery period
Commercial differentiation	Formulation, convenience, supply	No branded excipient opportunity
Clinical use	Selected diagnostic and treatment protocols	Established alternative

This comparison supports commercial opportunities centered on convenience, patient experience, predictable scheduling, and nuclear-medicine workflow rather than on excipient cost alone.

Key Takeaways

• Thyrogen is a lyophilized recombinant thyrotropin alfa biologic supplied in a 0.9 mg single-dose vial.
• Its labeled excipients are mannitol, sodium chloride, sodium phosphate dibasic, and sodium phosphate monobasic.
• Mannitol supports the lyophilized cake; phosphate controls pH; sodium chloride contributes to tonicity.
• The main excipient opportunities are qualified supply, dual sourcing, lyophilization optimization, and improved presentations.
• A ready-to-use liquid, dual-chamber device, or stabilized reformulation could create commercial value but would require substantial comparability work.
• Conventional generic and Paragraph IV pathways do not apply. Follow-on competition would proceed through biologic regulatory pathways.
• Thyrogen's strongest commercial protection is likely its biologic manufacturing, analytical, regulatory, and supply-chain complexity rather than a simple excipient patent.
• No standalone Thyrogen revenue is generally disclosed in Sanofi's public reporting, limiting precise product-level revenue exposure analysis.
• Hospitals and specialty centers may value supply reliability and preparation simplicity more than a low-cost excipient substitution.

FAQs

Can mannitol in Thyrogen be replaced with trehalose?

Yes, as a development concept, but replacement would constitute a formulation change requiring evidence on stability, potency, aggregation, lyophilized cake quality, reconstitution, and clinical comparability.

Is Thyrogen an interchangeable biosimilar?

No interchangeable biosimilar should be assumed. A future follow-on product would need separate FDA approval and, if seeking interchangeability, additional regulatory support beyond basic biosimilarity.

Does Thyrogen use polysorbate?

The U.S. prescribing information does not list polysorbate 20 or polysorbate 80 as Thyrogen excipients.[1]

Could a competitor commercialize a cheaper thyrotropin alfa vial?

A cheaper vial is possible in principle, but the sponsor would need to develop and obtain approval for a follow-on biologic. Manufacturing consistency, glycosylation, potency, immunogenicity, and clinical positioning would determine launch feasibility.

What is the most attractive excipient opportunity around Thyrogen?

The highest-value opportunity is not commodity excipient sales. It is a validated formulation and lyophilization package that improves stability, simplifies preparation, enables regional supply, or supports a differentiated ready-to-use presentation.

References

1. U.S. Food and Drug Administration. (2023). Thyrogen (thyrotropin alfa) prescribing information. Sanofi Genzyme.

2. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov

3. Sanofi. (2024). Annual report 2023. Sanofi.

4. European Medicines Agency. (2023). Thyrogen: Summary of product characteristics. https://www.ema.europa.eu